Your browser doesn't support javascript.
loading
Pathologic Response to Pretransplant Locoregional Therapy is Predictive of Patient Outcome After Liver Transplantation for Hepatocellular Carcinoma: Analysis From the US Multicenter HCC Transplant Consortium.
DiNorcia, Joseph; Florman, Sander S; Haydel, Brandy; Tabrizian, Parissa; Ruiz, Richard M; Klintmalm, Goran B; Senguttuvan, Srinath; Lee, David D; Taner, C Burcin; Verna, Elizabeth C; Halazun, Karim J; Hoteit, Maarouf; Levine, Matthew H; Chapman, William C; Vachharajani, Neeta; Aucejo, Federico; Nguyen, Mindie H; Melcher, Marc L; Tevar, Amit D; Humar, Abhinav; Mobley, Constance; Ghobrial, Mark; Nydam, Trevor L; Amundsen, Beth; Markmann, James F; Berumen, Jennifer; Hemming, Alan W; Langnas, Alan N; Carney, Carol A; Sudan, Debra L; Hong, Johnny C; Kim, Joohyun; Zimmerman, Michael A; Rana, Abbas; Kueht, Michael L; Jones, Christopher M; Fishbein, Thomas M; Markovic, Daniela; Busuttil, Ronald W; Agopian, Vatche G.
Afiliação
  • DiNorcia J; Dumont-UCLA (University of California, Los Angeles) Transplant and Liver Cancer Centers, Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA.
  • Florman SS; Recanati/Miller Transplantation Institute, Mount Sinai Medical Center, New York, NY.
  • Haydel B; Recanati/Miller Transplantation Institute, Mount Sinai Medical Center, New York, NY.
  • Tabrizian P; Recanati/Miller Transplantation Institute, Mount Sinai Medical Center, New York, NY.
  • Ruiz RM; Annette C. and Harold C. Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX.
  • Klintmalm GB; Annette C. and Harold C. Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX.
  • Senguttuvan S; Annette C. and Harold C. Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX.
  • Lee DD; Department of Transplantation, Mayo Clinic, Jacksonville, FL.
  • Taner CB; Department of Transplantation, Mayo Clinic, Jacksonville, FL.
  • Verna EC; New York-Presbyterian Hospital, Columbia University, New York, NY.
  • Halazun KJ; New York-Presbyterian Hospital, Weill Cornell, New York, NY.
  • Hoteit M; Penn Transplant Institute, University of Pennsylvania, Philadelphia, PA.
  • Levine MH; Penn Transplant Institute, University of Pennsylvania, Philadelphia, PA.
  • Chapman WC; Section of Transplantation, Department of Surgery, Washington University in St. Louis, St. Louis, MO.
  • Vachharajani N; Section of Transplantation, Department of Surgery, Washington University in St. Louis, St. Louis, MO.
  • Aucejo F; Cleveland Clinic Foundation, Cleveland, OH.
  • Nguyen MH; Division of Gastroenterology and Hepatology, Stanford University, Palo Alto, CA.
  • Melcher ML; Department of Surgery, Stanford University, Palo Alto, CA.
  • Tevar AD; Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA.
  • Humar A; Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA.
  • Mobley C; Sherrie & Alan Conover Center for Liver Disease & Transplantation, Houston Methodist Hospital, Houston, TX.
  • Ghobrial M; Sherrie & Alan Conover Center for Liver Disease & Transplantation, Houston Methodist Hospital, Houston, TX.
  • Nydam TL; Division of Transplant Surgery, Department of Surgery, University of Colorado School of Medicine, Denver, CO.
  • Amundsen B; Division of Transplant Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
  • Markmann JF; Division of Transplant Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
  • Berumen J; Division of Transplantation and Hepatobiliary Surgery, Department of Surgery, University of California, San Diego, San Diego, CA.
  • Hemming AW; Division of Transplantation and Hepatobiliary Surgery, Department of Surgery, University of California, San Diego, San Diego, CA.
  • Langnas AN; Department of Surgery, University of Nebraska Medical Center, Omaha, NE.
  • Carney CA; Department of Surgery, University of Nebraska Medical Center, Omaha, NE.
  • Sudan DL; Department of Surgery, Duke University Medical Center, Durham, NC.
  • Hong JC; Division of Transplant Surgery, Department of Surgery, Medical College of Wisconsin, Milwaukee, WI.
  • Kim J; Division of Transplant Surgery, Department of Surgery, Medical College of Wisconsin, Milwaukee, WI.
  • Zimmerman MA; Division of Transplant Surgery, Department of Surgery, Medical College of Wisconsin, Milwaukee, WI.
  • Rana A; Department of Surgery, Baylor College of Medicine, Houston, TX.
  • Kueht ML; Department of Surgery, Baylor College of Medicine, Houston, TX.
  • Jones CM; Section of Hepatobiliary and Transplant Surgery, University of Louisville School of Medicine, Louisville, KY.
  • Fishbein TM; Medstar Georgetown Transplant Institute, Georgetown University, Washington, DC.
  • Markovic D; Department of Biomathematics, David Geffen School of Medicine at UCLA, Los Angeles, CA.
  • Busuttil RW; Dumont-UCLA (University of California, Los Angeles) Transplant and Liver Cancer Centers, Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA.
  • Agopian VG; Dumont-UCLA (University of California, Los Angeles) Transplant and Liver Cancer Centers, Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Ann Surg ; 271(4): 616-624, 2020 04.
Article em En | MEDLINE | ID: mdl-30870180
OBJECTIVE: The aim of the study was to determine the rate, predictors, and impact of complete pathologic response (cPR) to pretransplant locoregional therapy (LRT) in a large, multicenter cohort of hepatocellular carcinoma (HCC) patients undergoing liver transplantation (LT). BACKGROUND: LRT is used to mitigate waitlist dropout for patients with HCC awaiting LT. Degree of tumor necrosis found on explant has been associated with recurrence and overall survival, but has not been evaluated in a large, multicenter study. METHODS: Comparisons were made among patients receiving pre-LT LRT with (n = 802) and without (n = 2637) cPR from the United States Multicenter HCC Transplant Consortium (UMHTC), and multivariable predictors of cPR were identified using logistic regression. RESULTS: Of 3439 patients, 802 (23%) had cPR on explant. Compared with patients without cPR, cPR patients were younger; had lower Model for End-stage Liver Disease (MELD) scores, AFP levels, and neutrophil-lymphocyte ratios (NLR); were more likely to have tumors within Milan criteria and fewer LRT treatments; and had significantly lower 1-, 3-, and 5-year incidence of post-LT recurrence (1.3%, 3.5%, and 5.2% vs 6.2%, 13.5%, and 16.4%; P < 0.001) and superior overall survival (92%, 84%, and 75% vs 90%, 78%, and 68%; P < 0.001). Multivariable predictors of cPR included age, sex, liver disease diagnosis, MELD, AFP, NLR, radiographic Milan status, and number of LRT treatments (C-statistic 0.67). CONCLUSIONS: For LT recipients with HCC receiving pretransplant LRT, achieving cPR portends significantly lower posttransplant recurrence and superior survival. Factors predicting cPR are identified, which may help prioritize patients and guide LRT strategies to optimize posttransplant cancer outcomes.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Fígado / Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged País/Região como assunto: America do norte Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Fígado / Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged País/Região como assunto: America do norte Idioma: En Ano de publicação: 2020 Tipo de documento: Article